Arrowhead Pharmaceuticals Inc (ARWR)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 29% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- Session momentumDown -6.9% — selling pressure-8
- 12-month trend+146% over the past year+10
- QualityRevenue growing 17% y/y-4
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 Dominant catalyst is product-related, driven by upcoming clinical data presentations. Continuation probability is moderate, as technical momentum supports the move but data readouts carry inherent uncertainty. Informational only — not financial advice.
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) Flashes Bull Flag Breakout Setup with Top-Tier Technical StrengthChartMill · 2026-08-26
- Arrowhead Pharmaceuticals To Present Data On Plozasiran In Patients With Severe Hypertriglyceridemia At European Society Of Cardiology CongressBenzinga · 2026-08-24
- Arrowhead Pharma’s REDEMPLO Authorized In EU; Now Prescribable And Reimbursable In Germany For Familial Chylomicronaemia SyndromeBenzinga · 2026-08-17
- Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook UpdatedYahoo · 2026-08-06
- ARWR: Acquires PRV for sNDA Submission for Plozasiran in sHTGYahoo · 2026-08-05
Any AI summary is an interpretation of public news, not advice or a price target.